Symbiotic AI is a Canadian digital health company developing AI-powered decision support solutions for cardiovascular care. The company applies machine learning and advanced analytics to large-scale clinical, imaging, and health system data to generate actionable insights that support treatment decisions for coronary artery disease (CAD). By analyzing patterns across patient characteristics, imaging findings, and clinical outcomes, Symbiotic AI’s technology helps clinicians evaluate treatment options such as medical therapy only, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) and prioritize on longevity, lifestyle, and care costs.
Symbiotic AI aims to advance improve heart care decisions with data science and help health systems deliver more efficient and sustainable care. The company works with hospital heart catheterization laboratories, cardiologists, health systems and insurers to translate complex clinical and imaging data into practical decision support tools.
Symbiotic AI’s solutions integrate with real-world clinical workflows, including hospital electronic health records, cardiovascular imaging systems, and clinical reporting and billing processes. This enables decision support to be delivered directly within existing care environments without disrupting physician workflows.
Overview of Symbiotic AI's flagship product, Revaz - https://www.youtube.com/watch?v=wdwutSFmAPI